The Cyclooxygenase-2 Inhibitor, Celecoxib, Prevents the Development of Mammary Tumors in HER-2/neu Mice

Cancer Epidemiology Biomarkers and Prevention

Volumn 12, Issue 12, 2003, Pages 1486-1491

  Lanza Jacoby, Susan ^a   Miller, Sheldon ^a   Flynn, John ^a   Gallatig, Kathleen ^a   Daskalakis, Constantine ^a   Masferrer, Jaime L ^b   Zweifel, Ben S ^b   Sembhi, Harjeet ^a   Russo, Irma H ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b PFIZER INC   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROSTACYCLIN; PROSTAGLANDIN E2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER INHIBITION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFICACY; FEMALE; GENE OVEREXPRESSION; HIGH RISK POPULATION; LUNG METASTASIS; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; TRANSGENIC MOUSE;

ANIMALS; BIOPSY, NEEDLE; BLOTTING, WESTERN; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; FEMALE; GENES, ERBB-2; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; PYRAZOLES; SENSITIVITY AND SPECIFICITY; SULFONAMIDES;

EID: 0346732943     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Jemal, A., Murray, T., Samuels, A., Ghafoor. A., Ward, E., and Thun, M. J. Cancer statistics, 2003. CA A Cancer J. Clin., 53: 5-26, 2003.
2. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., and Ullrich, A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Wash. DC), 244: 707-712, 1989.
3. Liu, X., and Rose, D. Differential expression and regulation of cyclooxygenase in two human breast cancer cells lines. Cancer Res., 55: 5125-5127, 1996.
4. Ristimaki, A., Sivula, A., Lundin, J., Lundin, M., Salminen, T., Haglund, C., Joensuu, H., and Isola, J. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res., 62: 632-635, 2002.
5. Jones, D. A., Carlton, D. P., McIntyre, T. M., Zimmerman, G. A., and Prescott, S. M. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J. Biol. Chem., 268: 9049-9054, 1993.
6. Prescott, S. M., and White, R. L. Self-promotion? Intimate connections between APC and prostaglandin H synthase-2. Cell, 8: 783-786, 1996.
7. Subbaramaiah, K., Altorki, N., Chung, W. J., Mestre, J. R., Sampat, A., and Dannenberg, A. J. Inhibition of cyclooxygenase 2 gene expression by p53. J. Biol. Chem., 274: 10911-10915, 1999.
8. Subbaramaiah, K., Norton, L., Gerald, W., and Dannenberg, A. J. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer. J. Biol. Chem., 277: 18649-18657, 2002.
9. Vadlamudi, R., Mandal, M., Adam, L., Steinbach, G., Mendelsohn, J., and Kumar, R. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene, 18: 305-314, 1999.
10. Liu, C. H., Chang, S. H., Narko, K., Trifan, O. C., Wu, M. T., Smith, E., Haudenschild, C., Lane, T. F., and Hla, T. Over-expression of cyclooxygenase (COX)-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem., 276: 18563-9, 2001.
11. Soslow, R., Dannenberg, A., Rush, D., Woemer, B. M., Khan, K. N., Masferrer, H., and Koki, A. T. Cox-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer (Phila.), 89: 2637-265, 2000.
12. Hwang, D., Scollard, D., Byrne, J., and Levine, E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J. Natl. Cancer Inst., 90: 455-460, 1998.
13. Half, E., Tang, X. M., Gwyn, K., Sahin, A., Wathen, K., and Sinicrope, F. A. Cyclooxygenase-2 expression in human breast cancer and adjacent ductal carcinoma in situ. Cancer Res., 62: 1676-1681, 2002.
14. Harris, R. E., Alshafie, G. A., Abou-Issa, H. M., and Seibert, K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res., 60: 2101-2103, 2000.
15. Alshafie, G. A., Abou-Issa, H. M., Seibert, K., and Harris, R. E. Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 (COX-2) Inhibitor, in rat mammary tumor model. Oncol. Rep., 7: 1377-1314, 2000.
16. Connolly, E. M., Harmey, J. H., O'Grady, T., Foley, Roche-Nagle, G., Kay, E., et al. Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer. Br. J. Cancer, 87: 231-237, 2002.
17. Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., and Muller, W. J., Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA., 89: 10578-10582, 1992.
18. Siegel, P. M., Dankort, D. L., Hardy, W. R., and Muller, W. J. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol. Cell. Biol., 14: 7068-7077, 1994.
19. Siegel, P. M., and Muller, W. J. Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation. Proc. Natl. Acad. Sci. USA, 93: 8878-8883, 1996.
20. Kundu, N., and Fulton, A. M. Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res., 62: 2343-2346, 2002.
21. Howe, L. R., Subbaramaiah, K., Patel, J., Masferrer, J. L., Deora, A., Hudis, C., Thaler, H. T., Muller, W. J., Du, B., Brown, A. M. C., and Dannenberg, A. J. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res., 62: 5405-5407, 2002.
22. Lanza-Jacoby, S., Flynn, J. T., and Miller, S. Parenteral supplementation with a fish-oil emulsion prolongs survival and improves rat lymphocyte function during sepsis. Nutrition, 17: 112-116, 2001.
23. Wu, K., Zhang, Y., Xiao-Chun, X., Hill, J., Celestino, J., Hee-Tae, K., Mohsin, S. K., Hilsenbeck, S. G., Lamph, W. W., Bissonette, R., and Brown, P. H. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res., 62: 6376-6380, 2002.
24. Niederberger, E., Tegeder, I., Vetter, G., Schmidtko, A., Schmidt, H., Euchenhofer, C., Brautigam, L., Grosch, S., and Geisslinger, G. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kb. FASEB J., 15: 1622-16664, 2001.
25. Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., and DuBois, R. N. Up-regulation of cyclooxygenase gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107: 1183-1188, 1994.
26. Chan, G., Boyle, J. O., Yang, E. K., Zhang, F., Sacks, P. G., Shah, J. P., Edelstein, D., Soslow, R. A., Koki, A. T., Woemer, B. M., Masferrer, J. L., and Dannenberg, A. J. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res., 59: 991-994, 1999.
27. Hida, T., Yatabe, Y., Achiwa, H., Muramatsu, H., Kozaki, K., Nakamura, S., Ogawa, M., Mitsudomi, T., Sugiura, T., and Takahashi, T. Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res., 58: 3761-3764, 1998.
28. Gupta, S., Srivastava, M., and Ahmad, N. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate, 42: 73-78, 2000.
29. Tucker, O. N., Dannenberg, A. J., Yang, E. K., Zhang, F., Teng, L., Daly, J. M., Soslow, R. A., Masferrer, J. L., Woerner, B. M., Koki, A. T., and Fahey, T. J. 3rd. Cyclooxygenase-2 expression is up-regulated in human pancreastic cancer. Cancer Res., 59: 987-990, 1999.
30. Kulkarni, S., Rader, J. S., Zhang, F., Liapis, H., Koki, A. T., Masferrer, J. L., Subbaramaiah, K., and Dannenberg, A. J. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res., 7: 429-434, 2001 Feb.
31. Tucker, M. J. The effect of long-term food restriction on tumors in rodents. Int. J. Cancer. 23: 803-807, 1979.
32. Kritchevsky, D., Weber, M. M., and Klurfeld, D. M. Dietary fat versus caloric content in initiation and promotion of 7, 12-dimethylbenz(a)anthracene-induced mammary tumorigenesis in rats. Cancer Res., 44: 3174-3177, 1984.
33. Klurfeld, D. M., Welch, C. B., Davis, M. J., and Kritchevsky, D. Determination of degree of energy restriction necessary to reduce DMBA-induced mammary tumorigenesis in rats during the promotion phase. J. Nutr., 119: 286-291, 1989.
34. Pape-Ansorge, K. A., Grande, J. P., Christensen, T. A., Maihle, N. J., and Cleary, M. P. Effect of moderate calorie restriction and/or weight-cycling on mammary tumor incidence and latency in MMTV-neu female mice. Nutr. Cancer, 44: 162-168, 2002.
35. Bennet, A., Charlier, E. M., McDonald, A. M., Simpson, J. S., and Stamford, I. F. Prostaglandins and breast cancer. Lancet, 2: 624-626, 1977.
36. Bennett, A., Berstock, D. A., Raja, B., and Stamford, I. F. Survival time after surgery is inversely related to the amounts of prostaglandins extracted from human breast cancers. Br. J. Pharmacol., 66: 451-455, 1970.
37. 2 levels in human breast cancer are associated with poor long-term survival. Proc. Am. Assoc. Cancer Res, 41: 3666A, 2000.
38. Kundu, N., Yang, Q., Dorsey, R., and Fulton, A. M. Increased cyclooxygenase-2 (COX-2) expression and activity in a murine model of metastatic breast cancer. Int. J. Cancer, 93: 681-686, 2001.
39. Shiff, S. J., Koutsos, M. I., Oiai, L. et al. Nonsteroidal antiinflammmatory drugs inhibit the cell proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp. Cell Res., 222: 179-188, 1996.
40. Husain, S. S., Szabo, I. L., Pai, R., Soreghan, B. et al. MAPK (ERK2) kinase-a key target for NSAIDs-induced inhibition of gastric cancer cell proliferation and growth. Life Sci., 69(25-26): 3045-3054, 2001.
41. Liu, X. H., Yao, S., Kirschenbaum, A. et al. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res., 58: 4245-4249, 1998.
42. Tsujii, M., Kawano, S., Tsuiji, S., Sawaoka, H., Hori, M., and DuBois, R. N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 93: 705-716, 1998.
43. Menard, S., Aiello, P., Tagliabue, E., Rumio, C., Lollini, P. L., Colnaghi, M. I., and Balsari, A. Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model. Cancer Res., 60: 273-275, 2000.
44. Jin, Z., and MacDonald, R. S. Soy isoflavones increase latency of spontaneous mammary tumors in mice. J. Nutr., 132: 3186-3190, 2002.
45. Slamon, D. J, Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pergram, M., Baselga, J., and Norton, L. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N. Engl. J. Med., 344: 783-792, 2001.
46. Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., and Arteaga, C. L. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res., 61: 8887-8895, 2001.